Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.700
-0.220 (-7.53%)
At close: Apr 28, 2026, 4:00 PM EDT
2.720
+0.020 (0.74%)
After-hours: Apr 28, 2026, 7:00 PM EDT
BDTX Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for BDTX stock have an average target of 9.50, with a low estimate of 6.00 and a high estimate of 14. The average target predicts an increase of 251.85% from the current stock price of 2.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 17, 2026.
Analyst Ratings
The average analyst rating for BDTX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $13 → $14 | Buy | Maintains | $13 → $14 | +418.52% | Mar 17, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $8 | Buy | Maintains | $9 → $8 | +196.30% | Jan 16, 2026 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 4, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $9 | Buy | Initiates | $9 | +233.33% | Nov 18, 2025 |
| Stifel | Stifel | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +196.30% | Oct 16, 2025 |
Financial Forecast
Revenue This Year
n/a
from 70.00M
Revenue Next Year
n/a
EPS This Year
-0.65
from 0.39
EPS Next Year
-0.96
from -0.65
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.28 | -0.47 | ||||||
| Avg | -0.65 | -0.96 | ||||||
| Low | -0.88 | -1.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.